142 related articles for article (PubMed ID: 15472518)
1. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein.
Dilger K; Schwab M; Fromm MF
Inflamm Bowel Dis; 2004 Sep; 10(5):578-83. PubMed ID: 15472518
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin.
Pauli-Magnus C; Mürdter T; Godel A; Mettang T; Eichelbaum M; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Mar; 363(3):337-43. PubMed ID: 11284449
[TBL] [Abstract][Full Text] [Related]
3. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.
Wandel C; Kim R; Wood M; Wood A
Anesthesiology; 2002 Apr; 96(4):913-20. PubMed ID: 11964599
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
Fujimoto H; Higuchi M; Watanabe H; Koh Y; Ghosh AK; Mitsuya H; Tanoue N; Hamada A; Saito H
Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
[TBL] [Abstract][Full Text] [Related]
6. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Zhu HJ; Wang JS; Donovan JL; Jiang Y; Gibson BB; DeVane CL; Markowitz JS
Eur J Pharmacol; 2008 Jan; 578(2-3):148-58. PubMed ID: 17963743
[TBL] [Abstract][Full Text] [Related]
7. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein.
Iwai M; Minematsu T; Li Q; Iwatsubo T; Usui T
Drug Metab Dispos; 2011 Dec; 39(12):2314-20. PubMed ID: 21918035
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
Kivistö KT; Zukunft J; Hofmann U; Niemi M; Rekersbrink S; Schneider S; Luippold G; Schwab M; Eichelbaum M; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):124-30. PubMed ID: 15322734
[TBL] [Abstract][Full Text] [Related]
9. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
Horie K; Tang F; Borchardt RT
Pharm Res; 2003 Feb; 20(2):161-8. PubMed ID: 12636153
[TBL] [Abstract][Full Text] [Related]
11. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K
Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657
[TBL] [Abstract][Full Text] [Related]
12. Transport studies with 5-aminosalicylate.
Xin HW; Schwab M; Klotz U
Eur J Clin Pharmacol; 2006 Oct; 62(10):871-5. PubMed ID: 16944117
[TBL] [Abstract][Full Text] [Related]
13. Effects of budesonide on P-glycoprotein expression in intestinal cell lines.
Maier A; Zimmermann C; Beglinger C; Drewe J; Gutmann H
Br J Pharmacol; 2007 Feb; 150(3):361-8. PubMed ID: 17179942
[TBL] [Abstract][Full Text] [Related]
14. Mediation of cimetidine secretion by P-glycoprotein and a novel H(+)-coupled mechanism in cultured renal epithelial monolayers of LLC-PK1 cells.
Dudley AJ; Brown CD
Br J Pharmacol; 1996 Mar; 117(6):1139-44. PubMed ID: 8882608
[TBL] [Abstract][Full Text] [Related]
15. Interaction of digoxin with antihypertensive drugs via MDR1.
Takara K; Kakumoto M; Tanigawara Y; Funakoshi J; Sakaeda T; Okumura K
Life Sci; 2002 Feb; 70(13):1491-500. PubMed ID: 11895100
[TBL] [Abstract][Full Text] [Related]
16. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease.
Levine A; Weizman Z; Broide E; Shamir R; Shaoul R; Pacht A; Dinari G; On A; Weiss B; Bujanover Y;
J Pediatr Gastroenterol Nutr; 2003 Feb; 36(2):248-52. PubMed ID: 12548062
[TBL] [Abstract][Full Text] [Related]
17. Directional transcellular transport of bisoprolol in P-glycoprotein-expressed LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK1 Cells.
Tahara K; Kagawa Y; Takaai M; Taguchi M; Hashimoto Y
Drug Metab Pharmacokinet; 2008; 23(5):340-6. PubMed ID: 18974611
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease.
Kwapisz L; Jairath V; Khanna R; Feagan B
Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):793-801. PubMed ID: 28612627
[TBL] [Abstract][Full Text] [Related]
19. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.
Farrell RJ; Menconi MJ; Keates AC; Kelly CP
Aliment Pharmacol Ther; 2002 May; 16(5):1021-31. PubMed ID: 11966513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
